Second Affiliated Hospital Of Guangzhou Medical University
Clinical trials sponsored by Second Affiliated Hospital Of Guangzhou Medical University, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a heart drug tame sepsis? new trial aims to find out Results expected Dec 2026 (estimated)
-
Can adding a fourth drug shrink large liver tumors that invade the portal vein?
Disease control Recruiting nowThis trial is testing whether adding hepatic arterial infusion chemotherapy (HAIC) to a combination of lenvatinib, sintilimab, and drug-eluting bead chemoembolization (DEB-TACE) can better control large liver cancers (over 7 cm) that have spread into the portal vein. About 320 pa…
Phase 2 • Sponsor: Second Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Gene therapy hopes to tame severe childhood epilepsy
Disease control Recruiting nowThis early-stage trial tests a gene therapy called RC001 in children aged 2 to 18 with Dravet syndrome, a severe form of epilepsy caused by a genetic mutation. The therapy is given as a single injection into the spinal fluid. The main goal is to check safety and how the body proc…
Early phase 1 • Sponsor: Second Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can a heart drug tame sepsis? new trial aims to find out
Disease control Recruiting nowThis study tests whether ivabradine, a drug that slows heart rate without weakening the heart's pumping strength, can help people with sepsis. Sepsis is a life-threatening infection that often causes a dangerously fast heart rate. The trial will enroll 172 adults in intensive car…
Phase 4 • Sponsor: Second Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can triple therapy kickstart diabetes remission? new study aims to find out
Disease control Recruiting nowThis study compares two triple-drug combinations to see which works better for controlling blood sugar and possibly achieving diabetes remission in people newly diagnosed with type 2 diabetes. About 240 adults aged 18-65 with very high blood sugar (HbA1c ≥9%) will be randomly ass…
Phase 1/2 • Sponsor: Second Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC